Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Hershey Co (HSY) Price & Performance

AbCellera Biologics IncTrade
Hershey CoTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Hershey Co — how do they compare? AbCellera Biologics Inc trades at $10.14 (market cap $2.99B), while Hershey Co trades at $183.84 (market cap $36.56B). The key difference: Hershey Co is far larger — about 12.2× AbCellera Biologics Inc's market cap, and Hershey Co pays a 3.19% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLHSY
Market Cap
$2.99B$36.56B
Sector
HealthConsumer Staples
52-Week High
$9.76$236.28
52-Week Low
$2.78$162.31
Enterprise Value
$2.58B$41.70B
Dividend Yield
3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Hershey Co

Hershey (HSY) trades at $183.19, up 0.24% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates by 33% and revenue growth of 4.5-5% guidance. Recent earnings show significant margin recovery to 45.3% as cocoa prices decline, supporting the stock's premium valuation at 24.86 P/E. Analyst consensus price target of $196.78 suggests 7.4% upside potential from current levels.

HSY presents a compelling investment case with improving fundamentals, dividend growth resumption, and margin expansion. However, risks include volume declines in salty snacks, competitive pressures, and potential cocoa price volatility. The stock's current technical overbought condition near resistance at $184 warrants caution despite positive earnings momentum and institutional support.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Hershey Co

Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.

Read more on HSY